Safety and Efficacy of AK0529 in Respiratory Syncytial Virus-Infected Infant Patients
A Phase 2 study evaluates the safety and efficacy of AK0529, an oral RSV fusion protein inhibitor, in infants aged 1-24 months hospitalized with RSV infection. The study found AK0529 to be well tolerated, with a significant reduction in viral load and Wang Respiratory Score at a dosage of 2 mg/kg bid.
© Copyright 2025. All Rights Reserved by MedPath